Background and objective: Birt-Hogg-Dubé syndrome (BHDS) is a rare hereditary disease that presents with multiple lung cysts and pneumothorax (PTX). Although some reports propose that findings from chest computed tomography enable one to distinguish BHDS from primary spontaneous pneumothorax (PSP), it is still unclear whether clinical features are useful for identifying patients with suspicion of BHDS from those with PTX. Methods: We retrospectively reviewed the medical records of patients with PTX who underwent videoassisted thoracoscopic surgery at Nissan Tamagawa Hospital from January 2012 to December 2015. Results: We identified a total of 1141 patients with PTX, including 54 with BHDS and 517 with PSP. Among them, logistic regression analysis segregated five features that were significantly associated with BHDS: familial history of PTX, past history of bilateral PTX, age at the first episode of PTX (≥25 years old (y.o.)), body mass index (≥18.5) and gender (female). We assigned scores of 3, 3, 2, 2 and 1 to the five features, respectively, to establish a system with a calculated score from 0 to 11. The cut-off value of a calculated score ≥ 4 yielded the highest sensitivity of 93% and specificity of 86%. Receiver operating characteristic (ROC) analysis showed the area under the curve reflecting an accuracy of this diagnostic test as 0.953. Conclusion: BHDS has several clinical features distinct from PSP. Our scoring system consists of only five clinical variables that are easily evaluated and efficiently separate BHDS patients from those who have PTX without relying on an imaging study. Further prospective study is needed to confirm our findings.
INTRODUCTION
Birt-Hogg-Dubé syndrome (BHDS), a hereditary genodermatosis, was first described in 1975 and 1977. 1, 2 Subsequent studies revealed that the candidate gene for BHDS was located on chromosome 17p11.2. This subsequently named FLCN gene is composed of 14 exons and encodes a protein called folliculin. [3] [4] [5] The indications of this syndrome are recognized as multiple lung cysts with recurrent pneumothorax (PTX), fibrofolliculomas of the skin and renal tumours. Among these clinical features, lung manifestations are the earliest to occur, usually at 20-30 years of age, whereas skin and renal manifestations do not appear until the 30s-50s. 6, 7 In particular, PTX presents with suddenonset shortness of breath and/or chest pain; therefore, patients with BHDS are often referred to outpatient or emergency departments, as PTX is the first presentation of the disease. Accordingly, pulmonologists and thoracic surgeons have a complex role if they are to establish the earliest possible diagnosis of BHDS, thereby benefitting patients by initiating periodic screenings for renal neoplasia.
Primary spontaneous pneumothorax (PSP), the most common type of PTX, is a spontaneously occurring air leakage into the pleural space. The disease usually
SUMMARY AT A GLANCE
The novel scoring system described here readily distinguishes Birt-Hogg-Dubé syndrome (BHDS) from primary spontaneous pneumothorax (PTX) by applying five clinical variables that are easily evaluated, are highly sensitive and have strong specificity. This system provides pulmonologists and thoracic surgeons a tool to avoid overlooking BHDS among the patients with PTX in daily clinical practice. occurs in thin, tall males at 10-20 years of age, but no clinically apparent underlying lung disease is involved. 8, 9 Patients with PSP develop subpleural blebs and bullae on an apical area of upper lobes and/or the superior segment of lower lobes. 10 In contrast, sufferers of BHDS develop multiple lung cysts that appear predominantly at the lower-medial zone of the lung field and adjacent to the interlobar fissure but sometimes abut peripheral pulmonary vessels. 11, 12 However, not yet evaluated is whether physical descriptions and clinical presentations such as body mass index (BMI), age of onset, incidence of familial history, smoking history, etc., characterize PTX due to BHDS and are useful for distinguishing BHDS from PSP.
Menko et al. recently reported two major and four minor diagnostic criteria for BHDS. 13 Of these, patients needed to fulfil one major or two minor criteria to confirm the diagnosis of BHDS. Among the three characteristic clinical manifestations, skin phenotype was designated as one of the major criteria, whereas both lung and kidney phenotypic conditions were minor criteria; bilateral basally located lung cysts with no other apparent cause, a characteristic finding on computed tomography (CT) of the chest, was included. Accordingly, for this assessment, CT of the chest is imperative to establish a lung phenotype that contributes to the diagnosis of BHDS. However, CT are not necessarily performed for all patients with PSP, especially in the setting of an emergency room or outpatient clinic. Therefore, we sought a practical way of diagnosing BHDS among patients with PXT without performing CT of the chest.
The crucial reason to distinguish BHDS from PSP in their early ages is the differences in terms of management and prognosis. Because multiple lung cysts of BHDS are located predominantly in the lower lung fields and interlobar area with some abutted to peripheral pulmonary vessels, conventional operative procedures such as resecting bullae using stapler and ligation are not feasible for the management of PTX in BHDS patients. On the other hand, early recognition of BHDS may benefit from periodic screening of renal neoplasia to detect its development in the earliest occasion.
The aim of this study is to clarify the clinical features of PTX in patients with BHDS and then to establish a scoring system that distinguishes BHDS from PSP among PTX patients.
METHODS

Study population
We retrospectively reviewed the medical records of the patients with PTX who underwent video-assisted thoracoscopic surgery (VATS) in the Pneumothorax Research Center at Nissan Tamagawa Hospital from January 2012 to December 2015. Among this population, the patients who were diagnosed as having BHDS and PSP were included in this study. The criteria for diagnosis of BHDS and PSP were as follows. In patients suspected of having BHDS because of a familial history of PTX and/or characteristic appearance of multiple lung cysts on chest CT, 11, 14 we established the diagnosis of BHDS by FLCN genetic testing (BHDS group). 15, 16 On the other hand, the diagnosis of PSP was made when (i) PTX occurred in otherwise healthy individuals with normal or essentially normal appearing lungs on CT images of the chest, and (ii) blebs and/or with bullae histologically confirmed in resected lung specimens (PSP group).
We compared the clinical characteristics between the PSP group and BHDS group: age at hospitalization, number of PTX episodes before hospitalization, gender, affected side of PTX, BMI, smoking habit, age at the first episode of PTX, familial history of PTX and history of bilateral PTX. This study was approved by the institutional review board of Nissan Tamagawa Hospital (approval number TAMA2016-006).
Establishment of the scoring system to differentiate BHDS from PSP Differences in the clinical features of patients with BHDS and PSP were analysed by using the chi-square test for categorical variables and Mann-Whitney test for quantitative variables. The quantitative data are presented as means AE SD. To select particular variables among clinical features to differentiate BHDS from PSP, backward stepwise selection was used and evaluated by the Akaike information criterion (AIC), and a multiple logistic regression analysis was used to assess the role of several variables as predictive factors for BHDS. The contribution of each potential predictive factor was denoted by an odds ratio and the associated 95% CI. We assigned the scores to each clinical variable found to be an independent predictor for the diagnosis of BHDS, weighted according to the beta coefficients from the multivariate logistic model. 17, 18 A receiver operating characteristic (ROC) curve was used to analyse the probability of BHDS dependent on the calculated score. Statistical analysis was considered to be significant when the P-value was <0.05. All analyses were performed using Stata/SE 14.0 for Mac (StatCorp LP, College Station, TX, USA).
RESULTS
Application of the scoring system to differentiate BHDS from PSP During the period from January 2012 to December 2015, 1141 patients underwent VATS for the treatment of PTX in the Pneumothorax Research Center at Nissan Tamagawa Hospital. Among this population, 54 (5%) subjects were patients with BHDS, whereas 517 (45%) had PSP. Their clinical characteristics are presented in Table 1 . Statistically significant differences were noted between BHDS and PSP groups in all variables tested excepting the number of PTX episodes before hospitalization. Notable differences found between the two groups were that the BHDS group was older and had features such as normal BMI, female preponderance, more habitual smokers, delayed age at the first episode of PTX, familial history of PTX and more episodes of bilateral and simultaneous PTX.
Forecasters of BHDS
To find the predictive factors for BHDS, we performed a backward stepwise selection with AIC and logistic regression analysis. The next step was to identify specific features that were significantly associated with BHDS. As a result, five features emerged as reliable predictors of BHDS: gender (female), BMI (≥18.5), age at the first episode of PTX (≥25 years old (y.o.)), familial history of PTX and past history of bilateral PTX (Table 2) . Based on these results, we assigned a weighted score to each of five clinical features to establish a scoring system (Table 3) . That system yielded a calculated score from 0 to 11 and a distribution of a total score for the BHDS and PSP groups as shown in Figure 1 . After testing different cut-off values, we selected the cut-off value of a calculated score ≥4, which yielded the highest sensitivity of 93% (95% CI: 82.1-98.0%) and specificity of 86% (95% CI: 82.6-88.8%) ( Table 4 ). The ROC curve reflects the accuracy of this diagnostic test; that is, area under the curve (AUC) was 0.953 (Fig. 2) .
DISCUSSION
This is the first study to demonstrate the statistically significant differences between patients with BHDS and PSP in clinical presentation (Table 1 ) and, thereby, to suggest their subsequent management pertinent to each disease. That is, the epidemiological characteristics of PSP, which is the most common cause of PTX, denote that PSP is apt to affect males (an annual incidence of 18-28/100 000 in males and 1.2-6.0/100 000 in females) and occurs in thin, tall and low BMI males between the ages of 10-30 years and rarely develops over the age of 40. 8, 9, 19 In contrast, the BHDS group is older, has a more normal BMI, no gender preponderance, delayed age at the first episode of PTX, familial history of PTX and more episodes of bilateral and simultaneous PTX. After evaluating all these factors, we speculated that these epidemiological differences between BHDS and PSP would enable us to establish a scoring system that distinguishes BHDS from PSP.
To develop a novel scoring system, as we previously reported, 18 we used a backward stepwise selection and multiple logistic regression analysis to select clinical factors, and an ROC curve to confirm the accuracy of the scoring system. Our final outcome yielded a novel clinical scoring system that identifies patients with suspicion of BHDS from those individuals with PTX. Our scoring system has a satisfactorily high sensitivity, specificity and AUC to separate patients with BHDS among Calculated score = Familial history of PTX (score 3 or 0) + history of bilateral PTX (score 3 or 0) + age at the first episode of PTX (≥25 years) (score 2 or 0) + gender (female) (score 2 or 0) + BMI (≥18.5) (score 1 or 0) . PTX, pneumothorax.
those with PTX by utilizing five clinical factors that are easily identified during the history-taking process in outpatient settings. The potential application of this scoring system is also relevant in the setting of emergency rooms where patients with PTX are likely to visit, often due to sudden-onset shortness of breath and/or chest pain. To reduce the frequently prolonged oversight of patients suspected of having BHDS, we recommend a process that includes: (i) using our scoring system for patients with PTX, (ii) calculating the score and (iii) if the score is ≥4, consider taking a CT of the chest to check whether the characteristic distribution of multiple lung cysts is present. The crucial reason to distinguish BHDS from PSP is that far different therapeutic methods should ensue. The pulmonary cysts of BHDS differ substantially from those of PSP 20, 21 ; that is, the pulmonary multiple cysts of BHDS are located predominantly in the lower lung fields, mediastinal sides and interlobar area. Those cysts are thin-walled, round-to oval-shaped and of varied sizes, with some abutted to peripheral pulmonary vessels. 11, 14, 22 Based on these presentations, the conventional treatment approach in which all subpleural cysts and bullae 22 are resected or subjected to pleuredosis 19, 23 is not feasible for the management of PTX in BHDS. Therefore, it is important for pulmonologists and thoracic surgeons to be aware of this rare cause of PTX and to consider a new therapeutic method such as the total pleural covering technique. 24, 25 This study had several limitations. First, our subjects were those who visited the Pneumothorax Research Center, which specializes in the treatment of PTX. Because many patients with intractable PTX are referred to this facility, our study population differed somewhat from those at other general hospitals. Accordingly, the clinical features of BHDS as well as PSP might be biased. On the other hand, our specialized facility for the treatment and management of PTX did have an opportunity of seeing many patients with such a rare lung disease like BHDS and enabled us to perform this study. Second, as we included only patients who underwent VATS for PSP and BHDS, those in our study might represent a skewed population that is not representative for all outpatient or emergency departments. Third, the cut-off value of 4 points consisted of age at the first episode of PTX (≥25 y.o.) and gender (female); therefore, the females' subcategories of PTX, such as lymphangioleiomyomatosis and catamenial PTX, are included. In such cases, further examinations are needed to distinguish BHDS from other PTX of females. 18, 22 Fourth, our scoring system may be slightly disadvantageous to male patients with BHDS as female gender gives a weighted score of 2 in our scoring system. If our system is applied to male BHDS patients in our population, it yielded a sensitivity of 81.8% and specificity of 91.6%, while the sensitivity of 100% and specificity of 57.5% was seen when applied to female BHDS patients. Finally, this was a retrospective cohort and a single institution study. Thus, we think further validation of our scoring system is needed to confirm its efficacy.
In conclusion, we have established a scoring system that has a high degree of sensitivity and specificity for distinguishing suspected BHDS from PSP, based on the assignment of weighted values to five clinical variables. These values are easily acquired from all patients with PTX in an outpatient department. This system could greatly reduce the likelihood that pulmonologists and thoracic surgeons might overlook BHDS among the patients with PTX in routine clinical practice and also eliminate the necessity of CT scans for diagnostic confirmation.
